Andromeda in Early Negotiations with American Pharma Company

Israel's Clal Biotechnology Industries said its subsidiary Andromeda Biotech is in early talks to be sold to an American drug company for a price that could reach hundreds of millions of dollars. Andromeda signed a memorandum of understanding to be sold to the unnamed firm, according to Clal, which owns 96 percent of Andromeda. Read the full story

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments